The role of iron in viral infections

Sophie Marion Schmidt

1Department of Anesthesia, Pain Management and Perioperative Medicine, Faculty of Medicine, Dalhousie University, NS, Canada

TABLE OF CONTENTS

1. Abstract
2. Introduction
   2.1. Human iron homeostasis
   2.2. Iron and the immune system
   2.3. Damaging effects of cellular iron
3. Iron in viral infections
   3.1. Role of iron in HBV infection
   3.2. Role of iron in HCV infection
   3.3. Role of iron in HCMV infection
   3.4. Role of iron in HIV infection
4. Conclusion
5. References

1. ABSTRACT

Crucial cellular processes such as DNA synthesis and the generation of ATP require iron. Viruses depend on iron in order to efficiently replicate within living host cells. Some viruses selectively infect iron – acquiring cells or influence the cellular iron metabolism via Human hemochromatosis protein (HFE) or hepcidin. During infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) iron overload is associated with poor prognosis for the patient and enhanced progression of the disease. Recent findings still lack to fully describe the viral interaction with the host iron metabolism during infection. This review summarizes the current knowledge of the viral regulation on the host cell iron metabolism in order to discuss the therapeutic option of iron chelation as a potential and beneficial adjuvant in antiviral therapy.

2. INTRODUCTION

2.1. Human iron homeostasis

Iron is an essential nutrient for humans with critical functions in many cellular processes (1), including DNA – synthesis, replication, repair and transcription (2). Iron deficiency affects the activity of iron - dependent enzymes and disrupts the proper function of different cellular processes (3). Iron functions as a redox catalyst and occurs as ferrous (Fe^{2+}) or ferric (Fe^{3+}) iron inside the cell.

Viruses depend on host cell survival during replication. The cellular metabolism is enhanced in order to support the necessary factors for replication and protein synthesis (2). These processes also require iron and therefore, iron chelation could improve antiviral treatment.

Iron uptake functions through divalent metal – iron transport protein 1 (DMT1) in the proximal duodenum or the heme carrier protein 1 (HCP1) in the jejunal enterocytes (4). In the duodenum ferric iron is reduced by ferric reductases present in the apical brush border of enterocytes. The correct subcellular location relies on a transport mechanism via ferritin. On the basolateral side the iron export is controlled by the membrane transporter ferroportin (FPN1) (5–7). In
The role of iron in viral infections

The cellular level of iron is regulated by iron regulatory proteins (IRP1/IRP2), which bind to iron – response elements (IRE). IREs are RNA hairpin structures in the untranslated region (UTR) of several cellular mRNAs like in the mRNA encoding ferritin or DMT1 (8). Systemically the peptide hormone hepcidin, which is itself produced in the liver, regulates the activity of FPN1 by binding to it and therefore inhibiting the cellular iron export. During an iron overload the hepcidin synthesis is increased leading to the internalization and degradation of FPN1. Despite the cellular homeostasis hepcidin also controls the export of iron into the plasma (9) (Figure 1).

2.2. Iron and the immune system

Hence pathogens require iron as a nutrient, iron deprivation serves as an innate immune mechanism against invading pathogens (1). One of the most important regulators is hepcidin, which is upregulated during inflammation by pro inflammatory cytokines, Toll like receptors (TLR) and the induction of endoplasmatic reticulum unfolded response. Hepcidin limits the extracellular iron through the internalization and degradation of FPN1. Despite the cellular homeostasis hepcidin also controls the export of iron into the plasma (9) (Figure 1).

2.3. Damaging effects of cellular iron

Despite being an essential nutrient, iron also bears damaging potential for the cell. During the Fenton reaction hydroxyl radicals are being generated by reducing ferrous to ferric iron. The generated hydroxyl radicals damaging lipids, DNA and proteins (1). Iron accumulation and overdose therefore also leads to increased oxidative stress and DNA damage, genetic instability and carcinogenesis (16). The reactive oxygen species (ROS) produced at high levels of cellular iron or rather hydroxyl radicals lead to destabilization and breakdown of the phospholipid membrane. This process leads to ferroptosis, an iron-dependent cell death mechanism (17, 18). ROS can attack cellular components and are further able to induce systemic damage like hepatic, cardiovascular and pancreatic dysfunctions (19, 20).
The role of iron in viral infections

3. IRON IN VIRAL INFECTIONS

3.1. Role of iron in HBV infection

The *hepatitis B virus* (HBV) is a partially double-stranded DNA–virus (21, 22), and belongs to the family of *Hepadnaviridae* (23). HBV causes chronic liver diseases, like chronic hepatitis B (CHB), liver cirrhosis (LC) and hepatocellular carcinoma (HCC). Approximately 240 million people are affected by hepatitis B infections and associated diseases worldwide (24, 25).

In 40% of patients with CHB elevated levels of iron in liver tissue were detected and linked to severity of the corresponding liver disease (26). Higher serum iron levels correlated with worse outcomes and prognosis for patients with CHB (27).

Wei *et al.* showed that serum iron levels were lower in HBV – related HCC patients compared to CHB and HBV – related LC – patients. In the named study iron levels negatively correlated with tumor size. It was suggested that the concentration of functional iron in the peripheral blood is low or normal, while the concentration of functional iron in tissue is high. Elevated iron levels were associated with enhanced progression of chronic HBV – infection and poor prognosis for the patient. Therefore, it was recommended to investigate iron chelation as a novel adjuvant for HCC therapy (28). Additionally, a study performed in 2016, showed that

---

**Figure 1.** Iron Homeostasis. Iron uptake functions through the divalent metal – iron transport protein 1 (DMT1). In the duodenum ferric iron is reduced by ferric reductases present in the apical brush border of enterocytes. The correct subcellular location relies on a transport mechanism via ferritin. On the basolateral side the iron export is controlled by the membrane transporter ferroportin (FPN1). In the extracellular space iron is oxidized to ferric iron by the ferroxidase. By binding to transferrin (Tf), ferric iron can be transported to special target cells. Inside the cells iron takes part in the biosynthesis of heme in mitochondria. Iron can be transported into endosomes via DMT-1. Furthermore, ferritin also acts as a storage for cellular iron. The peptide hormone hepcidin regulates the activity of FPN1 by binding to it and therefore inhibiting the cellular iron export. Intracellularly Iron responsive proteins control iron metabolism by binding to iron – response elements (IRE).
The role of iron in viral infections

The combination of Sorafenib with the iron chelator deferasirox led to a higher rate of apoptosis in HCC, compared to single drug treatment (29).

A study by Felton et al. in 2006 also showed that elevated serum iron levels are associated with a higher prevalence of HBV infection (30). Gao et al. found in 2018 that serum iron and serum ferritin levels were elevated in patients with CHB. In this study they saw decreased serum transferrin levels and total binding capacity and increased transferrin saturation, findings that were supported by several other studies (22, 23, 28, 29). It was postulated that increased iron release from infected and damaged hepatocytes is responsible for that. Additionally, persistent HBV carriers showed significantly higher levels of serum iron compared to patients with cleared viral infection (33).

Ohkoshi et al. showed in 2008 that in patients with HBV and LC the success of lamivudine treatment correlated with reduction in serum ferritin levels. The findings also showed that a successful antiviral therapy resolved the illness-related iron overload in these patients (34). Supporting Mao et al., 2015 found a positive correlation between serum iron, ferritin and alanine aminotransferase (ALT) levels. It was suggested that in cirrhotic patients HBV related liver injury, but not the HBV infection itself may be cause changes in serum iron markers (32). Furthermore, mean hepcidin levels were elevated in patients with CHB, leading to iron overload (35, 36). In patients with CHB iron overload could be due to liver injury (30), viral activity (30, 37), micro ribonucleic acid -122 (38), ROS (39), IL-6 (35) or other inflammatory factors (35). Mutations in the hemochromatosis gene (HFE), which lead to the following amino acid changes C282Y and H63D have shown deleterious effects in patients with CHB, causing iron overload and leading to steatosis and liver fibrosis (40).

The depletion of iron in HepG2 cells shows a decrease in HBV production (41). The question whether iron is promoting or inhibiting HBV replication is highly controversial. Several studies have shown the promoting effects of iron on HBV replication (42, 43), while others have shown detrimental effects (44, 45). The differing effects of iron could rely on the different stages of liver disease focused in the listed studies (Figure 2).

3.2. Role of iron in HCV infection

The hepatitis C virus (HCV), a member of the Hepacivirus C species, is a small, enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae (46). HCV is the cause of hepatitis C and several types of cancer such as HCC and lymphomas (47, 48) affecting approximately 177 million people worldwide (49).

Iron liver deposits have been observed in 7 – 61% of patients with chronic hepatitis c (CHC) and are associated with severity of the liver disease (50–52). Studies suggest, that a high level of iron in the liver plays a crucial role in the progression of liver disease and increasing the risk for liver cancer (53). Additionally, elevated iron levels were associated with poor response to interferon and ribavirin therapy (54). Effective interferon therapy has been shown to be capable of a significant decrease in iron liver deposits (51). Further the reduction of excess liver iron and body iron storages by phlebotomy ameliorated the course of chronic HCV among patients incapable of receiving interferon therapy (55). Phlebotomy was an approved antiviral therapy in the United States and Japan before the emerge of direct – acting antiviral agents (56–58).

Furthermore, a study by Di Bisceglie et al. in 1992 showed that HCV patients displayed elevated levels of serum ferritin, correlating with iron overload and inflammation of the liver (59). Ferritin levels have been described as strong predictors of severe liver fibrosis and steatosis and necro-inflammatory activity (54, 60). Studies showed, that high ferritin levels are correlated with ALT, aspartate transaminase (AST) and gamma-glutamyl transferase (GGT) levels (61). Iron supplementation in hemodialysis patients with HCV infection significantly increased transaminase levels after three months of therapy (62, 63).

Mesenchymal hepatic iron overload in the course of HCV infection has been suggested to be caused by hepatocyte necrosis, leading to the release of ferritin and iron uptake of macrophages and Kupffer cells (55). These events may contribute
The role of iron in viral infections

On a cellular level, the hemochromatosis gene (HFE) seems to play a role in promoting iron overload in HCV infected patients. Studies found, that homozygous and heterozygous mutations in HFE C282Y caused hepatic iron overload promoting steatosis and liver fibrosis in HCV – infected patients (40, 64–66).

Recent works have shown the beneficial role of iron on HCV translation in different HCV genotypes (67), but it remains unclear whether iron is suppressing or promoting HCV replication. By enhancing the function of the eukaryotic initiation factor elf3 and the La protein, iron seems to promote the translation of HCV mRNA (67, 68).

It was also investigated, that HCV is able to reduce the level of hepcidin through its core proteins E1, E2, NS3, NS4A, NS4B and NS5A by signal transduction and activation of the transcription, mitogen – activated protein kinase (MAPK), Bone morphogenetic proteins (BMP)/SMAD signaling pathways and an increased histone deacetylase (HDAC) activity (69, 70). These findings are further supported by Tumban et al., 2009 showing that the HCV – genome contains a RNA – structure mimicking iron responsive elements on its internal ribosome entry site, indicating that HCV has the ability to modulate the cellular iron metabolism (71). Low hepcidin levels lead to an increased ferroportin activity in the duodenum, upregulating intestinal iron

Figure 2. Iron and Hepatitis B virus. 40% of patients with CHB displayed elevated tissue iron. Furthermore, studies found elevated serum iron levels and elevated serum ferritin levels in infected patients. Additionally, studies found decreased serum transferrin level and elevated transferrin saturation. Several studies investigated the correlation between elevated serum iron and ferritin levels and ALT levels. Furthermore, patients with CHB had elevated He4pidin levels.
The role of iron in viral infections

absorption (72). In conclusion, HCV proteins seem to directly increase iron absorption, macrophage iron release and hepatic iron accumulation (73).

Recent discussions elucidate whether iron is a promoting factor for HCV replication in liver cells. Several studies have found that HCV replication is enhanced in iron overloaded macrophages compared to physiological iron level. This could be the result of high oxidative stress in the macrophages and an impaired immune function (74). A study by Kakizaki et al., 2000 showed that FeSO₄ in concentrations of 50 – 100µM enhanced HCV replication 10-fold in cultured human hepatocytes within 48 hours respectively to the untreated control (75). Nevertheless, other studies working with the neoplastic cell line Huh7 found that supra-physiologic iron concentrations induced by halmin inhibited HCV replication by inactivating RNA – polymerase NS5B (76, 77). Fillebeen et al., showed that HCV infection caused cellular iron depletion in Huh7 cells by increasing IRP activity and suppressing TfR1 and DMT -1 expression (78) (Figure 3).

3.3 Role of iron in HCMV infection

The human cytomegalovirus (HCMV) is an enveloped, double – stranded DNA – virus and belongs to the group of β – Herpesviruses (79). HCMV remains a major health burden with the world’s seroprevalence ranging between 40 – 99% depending on the geographical and socioeconomic background (80). Whereas HCMV infections remain mostly asymptomatic or display only mild symptoms in immunocompetent hosts, severe life – threatening symptoms are described for patients with an impaired adaptive immune system (81).

Studies have shown that the HCMV replication could be inhibited by the iron chelators deferoxamine (DFO) and calcium trinatrium diethylenetriaminepentaacetic acid (DPTA) (82, 83). A study by Sun et al. discovered a correlation between the HCMV protein pUL38 and the prevention of premature cell death due to antagonization of cellular stress response. It was shown that HCMV influences the iron metabolism in order to ensure cellular survival during viral replication. Through activating the ubiquitin – specific protease 24 (USP24), and thus reducing the release of free iron, pUL38 suppresses ferritinophagy. The cell death induced by infection with pUL38 – deficient HCMV could be inhibited by treatment with iron chelators like ciclopirox olamine or tiron (84).

Furthermore, another study found a connection between HCMV – infection and the nonclassical class I major histocompatibility complex molecule HFE. HFE is mutated in autosomal recessive iron overload disease hereditary hemochromatosis leading to a reduced iron intake via the transferrin receptor (85). The expression of the HCMV protein US2 interferes with the stability and assembly of hHFE complexes. US2 targets HFE specifically for proteasomal degradation leading to a decreased iron uptake. It remains unclear if this viral mechanism is used to alter cellular metabolism in order to escape immune response (86).

However, a study by Kaptein et al., 2006 identified the anti – malaria drug artesunate as a potential new antiviral drug, suggesting that its antiviral activity is enhanced by increased intracellular iron concentrations. Iron overload increases the production of reactive oxygen intermediates (ROI) and negatively influences signal transduction pathways like NF-κB which are crucial for HCMV’s replication (87) (Figure 4).

3.4. Role of iron in HIV infection

Even after the establishment of highly active antiretroviral therapy (HAART), HIV – infections remain a major cause of mortality worldwide (88). The United Nations estimate that currently 33 million individuals are infected with HIV worldwide (2).

Iron is important for DNA synthesis and repair (89). During an HIV – infection the body is set into a systemic inflammatory state (90, 91). HIV modulates cellular and systemic iron homeostasis (12, 92, 93), leading to lower hemoglobin (Hb) levels (94). Findings by Banjoko et al., in 2009 described elevated iron levels in antiretroviral therapy ART – naive HIV – positive patients (95), leading to the question whether HIV alters the iron homeostasis.
Studies have shown that anemia is associated with worse outcomes of HIV – infection (2). In contrast to that iron overload is also a risk factor for rapid progression of the disease (96). High cellular iron levels in macrophages lead to an increased HIV – transcription (97, 98). A study by Sappey et al. in 2009 revealed that the treatment with the iron chelator DFO led to a downregulation of NFκB in monocytes. The downregulation of NF-κB correlates with a decrease in HIV-1 reactivation probably caused by emerging oxidative stress (99). However, this effect was not seen in other studies examining the effect of iron chelation on NFκB – expression (100).

A different mechanism examined is the inhibition of the cyclin dependent kinases 2 (CDK2)/Cyclin E complex axis, in order to describe the relation between iron deficiency and reduced HIV replication, although it couldn’t be verified (101).

A study by Chang et al., 2014, showed that HIV – replication was enhanced in presence of higher iron levels. Iron supplementation increased viral replication and release. A decrease in cellular iron was protective against HIV – infection. Transferrin – receptor 1 (TfR-1) mRNA levels were increased due to HIV – infection, which led to an increased iron uptake and higher level of cellular iron. To examine whether ART was able to alter the cellular iron level, cells were treated with the protease inhibitor darunavir and nucleoside reverse transcriptase inhibitor tenofovir. The treatment increased TfR-1 levels and decreased ferroportin (FPN – 1) levels.
The role of iron in viral infections

Figure 4. Iron and Human cytomegalovirus. Studies found, that HCMV replication could be inhibited by iron chelators. Furthermore, HCMV seems to be able to suppress ferritinophagy. The virus interferes with the stability of the hHFE complex, therefore, suppressing iron intake. A study claimed, that ROS negatively influences crucial pathways for the HCMV.

(88). Tenofovir also targets the mitochondrial DNA – polymerase γ, leading to induced oxidative stress by altered iron levels (102, 103). In contrast the non – nucleoside reverse transcriptase inhibitor evafirenz didn’t alter cellular iron levels or the expression of iron regulatory genes (88).

In HIV – positive blood samples a significant increase in serum iron levels, transferrin saturation and a decrease in unsaturated binding capacity was examined. These effects even persisted under ART (88). Although other studies have shown that the overexpression of HIV – 1 Nef protein impaired the recycling of TIR-1 to the cell surface, which is therefore leading to reduced cellular iron uptake and iron deficiency (104, 105). This could be a strain – specific effect (106). Especially the influence of HIV on hepcidin levels has to be further investigated. Several studies have shown increased hepcidin levels during an HIV infection leading to reduced serum iron levels (88). Even though other studies have shown decreased hepcidin levels in HIV – positive women, which could be due to increased iron release into the circulation (107).

A recent study showed that HIV – infected
The role of iron in viral infections

Figure 5. Iron and Human immunodeficiency virus. In some studies, HIV – positive patients showed lower Hb – levels, which correlated with worse outcomes. Nevertheless, iron excess is also predictor for a progression of the disease. Studies found elevated serum iron levels, increased transferrin saturation, increased Transferrin - receptor 1 levels, leading to a higher iron intake. High iron level seems to support HIV – transcription, replication and release. A study investigated, that the iron chelator DFO decreased HIV – reactivation.

adults have a disrupted CNS iron transport, leading to mitochondrial degradation, owed to the fact that cellular iron is an important co – factor for mitochondrial biogenesis (108) (Figure 5).

4. CONCLUSION

The above discussed studies indicate the detrimental effects of iron overload in the setting of viral infections. The viruses discussed in this review are postulated to be able of altering the iron homeostasis in infected individuals. The viruses seem to prosper in the presence of iron overload; therefore, iron chelation appears to be a potential and logical beneficial adjuvant therapy for viral infections in an era of multidrug resistant viruses. However, further studies are needed to examine the precise interactions between iron homeostasis and viral proteins in order to improve actual and develop new therapeutic strategies.
The role of iron in viral infections

5. REFERENCES


6. A Donovan; A Brownlie; Y Zhou; J Shepard; SJ Pratt; J Moynihan; BH Paw; A Drejer; B Barut; A Zapata; TC Law; C Brugnara; SE Lux; GS Pinkus; JL Pinkus; PD Kingsley; J Palis; MD Fleming; NC Andrews; LI Zon. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 403, 776-781 (2000) DOI: 10.1038/35001596

7. AT McKie; P Marciani; A Rolfs; K Brennan; K Wehr; D Barrow; S Miret; A Bomford; TJ Peters; F Farzaneh; MA Hediger; MW Hentze; RJ Simpson. A Novel Duodenal Iron-Regulated Transporter, IREG1, Implicated in the Basolateral Transfer of Iron to the Circulation. Mol Cell 5, 299-309 (2000) DOI: 10.1016/S1097-2765(00)80425-6


The role of iron in viral infections


19. DM Zou; DD Rong; H Zhao; L Su; WL Sun. Improvement of chronic hepatitis B by iron chelation therapy in a patient with iron overload. Med (United States) 96 (2017) DOI: 10.1097/M.D.0000000000009566


23. SA Locarnini; M Roggendorf. Other Hepadnaviridae (Avihepadnaviridae (DHBV) and Orthohepadnaviridae (WHV)). In: Viral Hepatitis. John Wiley & Sons, Ltd, Oxford, UK (2013) DOI: 10.1002/9781118637272.ch7

24. JD Stanaway; AD Flaxman; M Naghavi; C Fitzmaurice; T Vos; I Abubakar; LJ Abu-Raddad; R Assadi; N Bhala; B Cowie; MH Forouzanfar; J Groeger; KM Hanafiah; KH Jacobsen; SL James; J MacLachlan; R Malekzadeh; NK Martin; AA Mokdad; AH Mokdad; CJL Murray; D Plass; S Rana; DB Rein; JH Richardus; D Sanabria; M Saylan; S Shahraz; S So; V Vlassov; E Weiderpass; ST Wiersma; M Younis; C Yu; M El Sayed Zaki; GS Cooke. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet (London, England) 388, 1081-1088 (2016) DOI: 10.1016/S0140-6736(16)30579-7


27. G Sebastiani; D Tempesta; A Alberti. Hepatic iron overload is common in chronic hepatitis B and is more severe in patients coinfected with hepatitis D virus. J Viral Hepat 19, e170-e176 (2012)
The role of iron in viral infections

DOI: 10.1111/j.1365-2893.2011.01508.x


29. S Urano; T Ohara; K Noma; R Katsube; T Ninomiya; Y Tomono; H Tazawa; S Kagawa; Y Shirakawa; F Kimura; K Nouso; A Matsukawa; K Yamamoto; T Fujiwara. Iron depletion enhances the effect of sorafenib in hepatocarcinoma. Cancer Biol Ther 17, 648-656 (2016) DOI: 10.1080/15384047.2016.1177677

30. C Felton; ED Lustbader; C Merten; BS Blumberg. Serum iron levels and response to hepatitis B virus. Proc Natl Acad Sci 76, 2438-2441 (2006) DOI: 10.1073/pnas.76.5.2438

31. O Yonal; F Akyuz; K Demir; S Ciftci; F Keskin; B Pinarbasi; A Uyanikoglu; H IIssever; S Ozdil; G Boztas; F Besisik; S Kaymakoglu; Y Cakaloglu; Z Mungan; A Oytun. Decreased Prohepcidin Levels in Patients with HBV-Related Liver Disease: Relation with Ferritin Levels. Dig Dis Sci 55, 3548-3551 (2010) DOI: 10.1007/s10620-010-1183-8

32. W Mao; Y Hu; Y Lou; Y Chen; J Zhang. Abnormal serum iron markers in chronic hepatitis B virus infection may be because of liver injury. Eur J Gastroenterol Hepatol 27, 130 (2015) DOI: 10.1097/MEG.0000000000000247

33. BS Blumberg; ED Lustbader; PL Whitford. Changes in serum iron levels due to infection with hepatitis B virus. Proc Natl Acad Sci U S A 78, 3222-4 (1981) DOI: 10.1073/pnas.78.5.3222

34. S Ohkoshi; A Yoshimura; S Yamamoto; M Yano; S Kurita; K Yamazaki; Y-H Aoki; S Yamagiwa; H Wakabayashi; M Sugiyama; T Takahashi; T Ishikawa; Y Matsuda; T Ichida; T Kamimura; Y Aoyagi. Successful treatment with lamivudine may correlate with reduction of serum ferritin levels in the patients with chronic hepatitis and liver cirrhosis type B. Hepatol Int 2, 382-7 (2008) DOI: 10.1007/s12072-008-9084-z


36. J Wang; A Dong; G Liu; GJ Anderson; TY Hu; J Shi; Y Hu; G Nie. Correlation of serum hepcidin levels with disease progression in hepatitis B virus-related disease assessed by nanopore film based assay. Sci Rep 6, 34252 (2016) DOI: 10.1038/srep34252


38. M Castoldi; M Vujic Spasic; S Altamura; J Elmén; M Lindow; J Kiss; J Stolte; R Sparla; LA D'Alessandro; U Klingmüller; RE Fleming; T Longerich; HJ Gröne; V Benes; S Kauppinen; MW Hentze; MU Muckenthaler. The liver-specific microRNA miR-122 controls systemic iron homeostasis in mice. J Clin Invest 121, 1386-96 (2011) DOI: 10.1172/JCI44883

39. J-M Gu; SO Lim; SJ Oh; S-M Yoon; JK Seong; G Jung. HBx modulates iron
The role of iron in viral infections

DOI: 10.1016/j.virusres.2007.12.014

40. A Piperno; A Vergani; I Malosio; L Parma; L Fossati; A Ricci; G Bovo; G Boari; G Mancia. Hepatic iron overload in patients with chronic viral hepatitis: Role of HFE gene mutations. Hepatology 28, 1105-1109 (1998) DOI: 10.1002/hep.510280427

41. P Chouteau; J Le Seyec; B Saulier-Le Dréan; I Cannie; P Brisset; G Lescoat; C Guguen-Guillouzo; P Gripom. Inhibition of hepatitis B virus production associated with high levels of intracellular viral DNA intermediates in iron-depleted HepG2.2.15 cells. J Hepatol 34, 108-113 (2001) DOI: 10.1016/S0168-8278(00)00110-X


45. C Fang; C Zhao; X Liu; P Yang; H Lu. Protein alteration of HepG2.2.15 cells induced by iron overload. Proteomics 12, 1378-1390 (2012) DOI: 10.1002/pmic.201100335


47. C Ferri; M Sebastiani; D Giuggioli; M Colaci; P Fallahi; A Pliuso; A Antonelli; AL Zignego. Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non- Hodgkin’s lymphoma, and cancer, (2015) DOI: 10.4254/wjh.v7.i3.327


50. IS SILVA; RM PEREZ; P V OLIVEIRA; MI CANTAGALO; E DANTAS; C SISTI; C FIGUEIREDO-MENDES; VP LANZONI; AE SILVA; MLG FERRAZ. Iron overload in patients with chronic hepatitis C virus infection: Clinical and histological study. J Gastroenterol Hepatol 20, 243-248 (2005) DOI: 10.1111/j.1440-1746.2004.03549.x

51. E Boucher; A Bourienne; P Adams; B
The role of iron in viral infections

52. RW Lambrecht; RK Sterling; D Naishadham; AM Stoddard; T Rogers; C Morishima; TR Morgan; HL Bonkovsky; the H-CT Group. Iron Levels in Hepatocytes and Portal Tract Cells Predict Progression and Outcome of Patients with Advanced Chronic Hepatitis C. Gastroenterology 140, 1490 (2011) DOI: 10.1053/j.gastro.2011.01.053

53. S Milic; I Mikolasevic; L Orlic; E Devoic; N Starevic-Cizmarevic; D Stimac; M Kapovic; S Ristic. The Role of Iron and Iron Overload in Chronic Liver Disease. Med Sci Monit 22, 2144-51 (2016) DOI: 10.12659/MSM.896494

54. CM Lange; Z Kutalik; K Morikawa; S Bibert; A Cerny; G Dollenmaier; J-F Dufour; TJ Gerlach; MH Heim; R Malinverni; B Müllhaupt; F Negro; D Moradpour; P-Y Bochud. Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy. Hepatology 55, 1038-1047 (2012) DOI: 10.1002/hep.24787


57. H Hayashi; A Piperno; N Tomosugi; K Hayashi; F Kimura; S Wakusawa; M Yano; Y Tatsumi; A Hattori; S Pelucchi; Y Katano; H Goto. Patients with Chronic Hepatitis C May be More Sensitive to Iron Hepatotoxicity than Patients with HFE-Hemochromatosis. Intern Med 49, 2371-2377 (2010) DOI: 10.2169/internalmedicine.49.4088

58. M Sartori; S Andorno; A Rossini; R Boldorini; C Bozzola; S Carmagnola; M Del Piano; E Albano. Phlebotomy improves histology in chronic hepatitis C males with mild iron overload. World J Gastroenterol 16, 596 (2010) DOI: 10.3748/wjg.v16.i5.596


60. C Vagu; C Sultana; S Ruta. Serum iron markers in patients with chronic hepatitis C infection. Hepat Mon 13, e13136 (2013) DOI: 10.5812/hepatmon.13136


62. A OZDEMIR; B YALINBAS; U SELAMET; M ERES; B MURAT; RU GURSU; Y BARUT. Relationship between iron replacement and hepatic functions in hepatitis C virus-positive chronic haemodialysis patients. Nephrology 10, 433-437 (2005) DOI: 10.1111/j.1440-1797.2005.00474.x
63. S Kahraman; R Yilmaz; G Genctoy; M Arici; B Altun; Y Erdem; U Yasavul; C Turgan. Efficacy and Safety of Intravenous Iron Therapy for HCV-Positive Haemodialysis Patients. Nephron Clin Pract 100, c78-c85 (2005) DOI: 10.1159/000085052

64. BC Smith; J Grove; MA Guzail; CP Day; AK Daly; AD Burt; MF Bassendine. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 27, 1695-1699 (1998) DOI: 10.1002/hep.510270631

65. L Valenti; EA Pulixi; P Arosio; L Cremonesi; G Biasiotto; P Dongiovanni; M Maggioni; S Fargion; AL Fracanzani. Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis. Haematologica 92, 1037-1042 (2007) DOI: 10.3324/haematol.11281


69. U Georgopoulou; A Dimitriadis; P Foka; E Karamichali; A Mamalaki. Hepcidin and the iron enigma in HCV infection, (2014) DOI: 10.4161/viru.28508

70. K Miura; K Taura; Y Kodama; B Schnabl; DA Brenner. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity, (2008) DOI: 10.1002/hep.22486


72. L Ma; T Zou; Y Yuan; J Lv; X Dong; G Yang; Y Zhu; J Luo; Z Zhang; J Yang. Duodenal Ferroportin Is Up-Regulated in Patients with Chronic Hepatitis C. PLoS One 9, e110658 (2014) DOI: 10.1371/journal.pone.0110658

73. S Nishina; K Hino; M Korenaga; C Vecchi; A Pietrangelo; Y Mizukami; T Furutani; A Sakai; M Okuda; I Hidaka; K Okita; I Sakaida. Hepatitis C Virus-Induced Reactive Oxygen Species Raise Hepatic Iron Level in Mice by Reducing Hepcidin Transcription, (2008) DOI: 10.1053/j.gastro.2007.10.011

74. XL Cao; MF Zhao; DG Li; Y Xing; YC Zhang; J Chen; XY He; R Cui; JX Meng; X Xiao; J Mu; YY Jiang; RM Wu. [Establishment of macrophage model of iron overload in vitro and the injury induced by oxidative stress on macrophage with iron overload]., (2016)

75. S Kakizaki; H Takagi; N Horiguchi; M
The role of iron in viral infections


76. C Fillebeen; AM Rivas-Estilla; M Bisaillon; P Ponka; M Muckenthaler; MW Hentze; AE Koromilas; K Pantopoulos. Iron inactivates the RNA polymerase NS5B and suppresses subgenomic replication of hepatitis C virus, (2005) DOI: 10.1074/jbc.M412687200

77. G Bartolomei; RE Cevik; A Marcello; RE Cevik3; AM Correspondence; A Marcello. Modulation of hepatitis C virus replication by iron and hepcidin in Huh7 hepatocytes. J Gen Virol 92, 2072-2081 (2011) DOI: 10.1099/vir.0.032706-0


79. V Schottstedt; J Blümel; R Burger; C Drosten; A Gröner; L Gürtler; M Heiden; M Hildebrandt; B Jansen; T Montag-Lessing; R Offergeld; G Pauli; R Seitz; U Schlenkrich; J Strobel; H Willkommen; C-HW von König. Human Cytomegalovirus (HCMV) - Revised. Transfus Med Hemother 37, 365-375 (2010) DOI: 10.1159/000322141


81. MT Nogalski; D Collins-McMillen; AD Yurochko. Overview of human cytomegalovirus pathogenesis, (2014) DOI: 10.1007/978-1-62703-788-4_2


84. Y Sun; Q Bao; BB Xuan; WW Xu; D Pan; Q Li; Z Qian; Z Quain. Human Cytomegalovirus Protein pUL38 Prevents Premature Cell Death by Binding to Ubiquitin - Specific Protease 24 and Regulating Iron Metabolism. J Virol 92, 1-17 (2018) DOI: 10.1128/JVI.00191-18

85. Feder JN; Gnirke A; Thomas W; Tsuchihashi Z; Ruddy DA; Basava A. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis, (1996) DOI: 10.1038/ng0896-399

86. S V. Ben-Arieh; B Zimerman; NI Smorodinsky; M Yaucubovicz; C Schechter; I Back; J Gibbs; JR Bennink; JW Yewdell; JE Coligan; H Firat; F Lemonnier; R Ehrlich. Human Cytomegalovirus Protein US2 Interferes with the Expression of Human HFE, a Nonclassical Class I Major Histocompatibility Complex Molecule That Regulates Iron Homeostasis, (2002) DOI: 10.1128/JVI.75.21.10557-10562.2001

87. SJF Kaptein; T Efferth; M Leis; S
The role of iron in viral infections

Rechter; S Auerochs; M Kalmer; CA Bruggeman; C Vink; T Stamminger; M Marschall. The anti-malaria drug artemesunate inhibits replication of cytomegalovirus in vitro and in vivo. Antiviral Res 69, 60-69 (2006) DOI: 10.1016/j.antiviral.2005.10.003


89. M Bayeva; H-C Chang; R Wu; H Ardehali. When less is more: novel mechanisms of iron conservation. Trends Endocrinol Metab 24, 569-77 (2013) DOI: 10.1016/j.tem.2013.07.003


93. M Nairz; D Haschka; E Demetz; G Weiss. Iron at the interface of immunity and infection. Front Pharmacol 5, 152 (2014) DOI: 10.3389/fphar.2014.00152


96. JR Delanghe; MR Langlois; JR Boelaert; J Van Acker; F Van Wanzeele; G Van Der Groen; R Hemmer; C Verhofstede; M De Buyzere; D De Bacquer; V Arendt; J Plum. Haptoglobin polymorphism, iron metabolism and mortality in HIV infection. Aids 12, 1027-1032 (1998) DOI: 10.1097/00002030-199809000-00010


98. S Nekhai; N Kumari; S Dhawan. Role of cellular iron and oxygen in the regulation of HIV-1 infection. Future Virol 8, 301-311 (2013) DOI: 10.2217/fvl.13.6

99. C SAPPEY; JR BOELAERT; S LEGRAND-POELS; C FORCEILLE; A FAVIER; J PIETTE. Iron Chelation decreases NF-κB and HIV Type 1 Activation due to oxidative Stress. AIDS Res Hum Retroviruses 11, 1049-1061 (2009)
The role of iron in viral infections

DOI: 10.1089/aid.1995.11.1049

100. Z Debebe; T Ammosova; D Breuer; DB Lovejoy; DS Kalinowski; PK Karla; K Kumar; M Jerebtsova; P Ray; F Kashanchi; VR Gordeuk; DR Richardson; S Nekhai. Iron Chelators of the Di-2-pyridylketone Thiosemicarbazone and 2-Benzoylpyridine Thiosemicarbazone Series Inhibit HIV-1 Transcription: Identification of Novel Cellular Targets-Iron, Cyclin-Dependent Kinase (CDK) 2, and CDK9. Mol Pharmacol 79, 185-196 (2011) DOI: 10.1124/mol.110.069062


102. JJ Kohler; SH Hosseini; A Hoving-Brandt; E Green; DM Johnson; R Russ; D Tran; CM Raper; R Santoianni; W Lewis. Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest 89, 513-9 (2009) DOI: 10.1038/labinvest.2009.14

103. AC de Bragança; D Canale; JG Gonçalves; MHN Shimizu; AC Seguro; RA Volpini. Vitamin D Deficiency Aggravates the Renal Features of Moderate Chronic Kidney Disease in 5/6 Nephrectomized Rats. Front Med 5 (2018) DOI: 10.3389/fmed.2018.00282

104. R Madrid; K Janvier; D Hitchin; J Day; S Coleman; C Noviello; J Bouchet; A Benmerah; J Guatelli; S Benichou. Nef-induced alteration of the early/recycling endosomal compartment correlates with enhancement of HIV-1 infectivity. J Biol Chem 280, 5032-44 (2005) DOI: 10.1074/jbc.M401202200

105. H Drakesmith; N Chen; H Ledermann; G Screaton; A Townsend; X-N Xu. HIV-1 Nef down-regulates the hemochromatosis protein HFE, manipulating cellular iron homeostasis. Proc Natl Acad Sci U S A 102, 11017-22 (2005) DOI: 10.1073/pnas.0504823102

106. H Koppensteiner; K Höhne; MV Gondim; F-X Gobert; M Widder; S Gundlach; A Heigele; F Kirchhoff; M Winkler; P Benaroch; M Schindler. Lentiviral Nef suppresses iron uptake in a strain specific manner through inhibition of Transferrin endocytosis. Retrovirology 11, 1 (2014) DOI: 10.1186/1742-4690-11-1


108. SR Mehta; J Pérez-Santiago; T Hulgan; TRC Day; J Barnholtz-Sloan; H Gittleman; S Letendre; R Ellis; R Heaton; S Patton; JD Suben; D Franklin; D Rosario; DB Clifford; AC Collier; CM Marra; BB Gelman; J McArthur; A McCutchan; S Morgello; D Simpson; J Connor; I Grant; A Kallianpur. Cerebrospinal fluid cell-free mitochondrial DNA is associated with HIV replication, iron transport, and mild HIV-associated neurocognitive impairment. J Neuroinflammation 14, 72 (2017) DOI: 10.1186/s12974-017-0848-z

Abbreviations: HBV: hepatitis B virus, HCV:

**Key Words:** HBV, HCV, HIV, Iron, Immune system, HFE, iron chelation, Review

**Send correspondence to** Sophie Marion Schmidt, Department of Anesthesia, Pain Management and Perioperative Medicine, Faculty of Medicine, Dalhousie University, NS, Canada, Tel: 902-494-1287, Fax: 902-494-2493, E-mail: sophiemarschmidt@icloud.com